Vestal Point Capital LP Has $20.70 Million Stock Position in Liquidia Co. (NASDAQ:LQDA)

Vestal Point Capital LP boosted its stake in Liquidia Co. (NASDAQ:LQDA - Free Report) by 17.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,760,000 shares of the company's stock after buying an additional 260,000 shares during the period. Vestal Point Capital LP owned 2.08% of Liquidia worth $20,698,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in LQDA. JPMorgan Chase & Co. increased its position in Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after buying an additional 210,753 shares during the period. DMC Group LLC grew its stake in shares of Liquidia by 17.4% in the fourth quarter. DMC Group LLC now owns 16,302 shares of the company's stock worth $192,000 after purchasing an additional 2,419 shares in the last quarter. Catalina Capital Group LLC grew its stake in shares of Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock worth $215,000 after purchasing an additional 1,125 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Liquidia by 3.5% in the fourth quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock worth $948,000 after purchasing an additional 2,741 shares in the last quarter. Finally, Sigma Planning Corp grew its stake in shares of Liquidia by 3.4% in the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock worth $767,000 after purchasing an additional 2,115 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Trading Down 1.3%

LQDA stock traded down $0.21 during trading hours on Friday, hitting $15.35. 4,742,122 shares of the stock traded hands, compared to its average volume of 1,065,159. Liquidia Co. has a one year low of $8.26 and a one year high of $19.41. The company has a market cap of $1.31 billion, a P/E ratio of -9.42 and a beta of 0.24. The stock has a 50-day simple moving average of $14.74 and a 200 day simple moving average of $13.57.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on LQDA. HC Wainwright reissued a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research note on Monday, May 12th. Raymond James increased their price target on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research note on Friday, May 9th. Oppenheimer set a $13.00 price target on Liquidia and gave the stock an "underperform" rating in a research note on Monday, May 19th. Scotiabank reissued an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. Finally, Wall Street Zen raised Liquidia from a "sell" rating to a "hold" rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.56.

Insider Buying and Selling

In other news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the transaction, the chief executive officer now owns 1,006,420 shares of the company's stock, valued at approximately $13,657,119.40. This represents a 1.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jason Adair sold 1,856 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,138 shares of company stock valued at $450,233. Corporate insiders own 26.50% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).